Compared with Trastuzumab alone, a combined regimen of Pyrrolitinib and Trastuzumab is equally safe, and improving immune function, reducing the level of tumor markers, and improving tumor response in patients with HER-2 positive BC. This evidence concerns the gene ERBB2 and neoplasm.